A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus for Tunisian Adults after Renal Transplantation

Abstract

Background: Tacrolimus is the most frequently used immunosuppressive drug for preventing renal rejection. However, its use is hampered by its narrow therapeutic index and large intra and interpatient variability in pharmacokinetics. The objective of this study was to externally validate a tacrolimus population pharmacokinetic model developed for the Dutch population and adjust the model for the Tunisian population for use in predicting the starting dose requirement after kidney transplantation. Methods: Data on tacrolimus exposure were obtained from kidney transplant recipients (KTRs) during the first 3 months post-transplantation. External validation of the Dutch model and its adjustment for the Tunisian population was performed using nonlinear mixed-effects modeling. Results: In total, 1901 whole-blood predose tacrolimus concentrations from 196 adult KTRs were analyzed. According to a visual predictive check, the Dutch model underestimated the starting dose for the Tunisian adult population. The effects of age, together with the CYP3A5*3 and CYP3A4*22 genotypes on tacrolimus clearance were significantly different in the Tunisian population than in the Dutch population. Based on a bodyweight-based dosing, only 21.9% of tacrolimus concentrations were within the target range, whereas this was estimated to be 54.0% with the newly developed model-based dosing. After adjustment, the model was successfully validated internally in a Tunisian population. Conclusions: A starting-dose population pharmacokinetic model of tacrolimus for Tunisian KTRs was developed based on a previously published Dutch model. Using this starting dose could potentially increase the percentage of patients achieving target tacrolimus concentrations after the initial starting dose.

CYP3A4*18B, CYP3A5*3, and MDR1C3435T gene studies with tacrolimus pharmacokinetics in healthy Chinese subjects

“…14 Patients with CYP3A5-expressing genotypes require 1.5 to 2 times the dose of tacrolimus to achieve the same blood concentration. [15][16][17][18] The tacrolimus analysis of the subjects in this study who received the same dose showed that the AUC values of the CYP3A5-nonexpressing genotype were 1-2.5 times greater than the AUC values of the CYP3A5-expressing genotype in a healthy Chinese population. The MDR1 gene encodes P-gp, which is responsible for translocating tacrolimus to the extracellular environment.…”